Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. - Wikidata - wikimedia - TriplyDB

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

http://www.wikidata.org/entity/Q39280062

about

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Synthetic biology approaches to engineer T cells Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy Enhancing adoptive T cell immunotherapy with microRNA therapeutics.Noncanonical roles of the immune system in eliciting oncogene addiction Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Immunotherapy of cancers comes of age.A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.Virus-Specific T Cells for the Immunocompromised Patient.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Dexamethasone induced apoptosis of A549 cells via the TGF-β1/Smad2 pathway.Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.CAR T Cell Therapy for Neuroblastoma

P2860

Q26778759-5C702711-E8DA-4C17-8C3E-2B32B282D714 Q26798366-4DC2DAAE-D779-40AC-B209-BCA1CA8B693A Q28075996-C7A91777-37B8-4885-9159-57F981EC0C95 Q34361976-1B68CDAB-6D6B-422A-93FF-66831C6E3972 Q35145392-6491729D-4205-4A00-B0CA-B3D9C9FAB1CE Q35980893-78E1EBB2-B1C2-4B5A-903B-29F4369E84D6 Q36143408-739DBEA2-6469-4A89-81A7-FF4775EB351D Q36830759-146E61BA-5068-429A-B1CD-B87EFDCC2112 Q36889204-7E0AD087-9FD0-4B30-88E4-C6F1FC8E08C3 Q36931816-CD265DBD-9B19-4EAF-804B-E60E4C0ECF38 Q37126006-F17A5725-BF4A-4B0B-BC8F-58713A84EF2A Q37716633-D01AE777-34D6-4667-AAD6-887DCD621342 Q38753973-A9C09E46-C6E0-4085-8E11-AF242079C3B7 Q38811497-18A12268-668F-4947-9E5F-342B0403061C Q39039017-7AEE0A95-8D16-4339-B477-F882672D1876 Q39194733-769CABA7-F2A3-4D50-BE61-9FAE4E02D3D3 Q40099075-F5881B21-37E1-412F-A0E9-1372C109B2D8 Q41203830-1183DFE4-5505-4DBE-BD09-1B471101D6FB Q41208347-2698DAD7-89D1-4A0A-BEB4-CB4341A6861F Q42654381-F2130D7E-4B4D-420E-B66D-9B8C26FB6199 Q47285613-31C7574D-E0EE-45BB-BBAC-B39B9749F944 Q50045889-67C4479F-465F-464C-82CC-02A698C77785 Q54965277-7E3A2734-5673-4F4C-9B42-CED421B0A020 Q59127901-4D41E88D-F715-4D80-980A-5B98D35D04C9

P2860

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

http://www.wikidata.org/entity/Q39280062

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Inhibition of TGF-β signaling ...... nces tumor treatment efficacy.

@en

Inhibition of TGF-β signaling ...... nces tumor treatment efficacy.

@nl

type

label

Inhibition of TGF-β signaling ...... nces tumor treatment efficacy.

@en

Inhibition of TGF-β signaling ...... nces tumor treatment efficacy.

@nl

prefLabel

Inhibition of TGF-β signaling ...... nces tumor treatment efficacy.

@en

Inhibition of TGF-β signaling ...... nces tumor treatment efficacy.

@nl

P1433

Q39280062-A360B264-AEB9-4CD9-9ABE-E14B53C1AE61

P1476

Q39280062-B523C0D2-A982-49C1-9652-82F0F559E387

P2093

Q39280062-07E4743D-9CE4-47A6-B990-DDF541018D91

Q39280062-3DABFCD8-37C1-43E2-BC00-96FF80CFE4CC

Q39280062-BF64428E-653C-4897-8829-41746B6EF404

Q39280062-ED3D5C48-66A0-4F49-94AD-797A457B7E0D

Q39280062-F9C80578-29FE-48C6-ABF9-099B9E4C0EEB

P2860

Q39280062-019D6099-4D6C-46DF-86DF-79395A5B8CBB

Q39280062-02EE95BE-B1D0-489B-86E0-58A45F003089

Q39280062-081FE5A2-6162-48CB-AD37-20CEB14AEE8C

Q39280062-108F7831-C1B3-4E4F-82EA-C7D6DB175B41

Q39280062-118AD337-B457-438B-9804-01B0538B996F

Q39280062-22246B0E-8FB3-4BD6-BB29-EF698DE65309

Q39280062-2B5E85E2-6CA2-4DE5-A78F-A380B39A4AFD

Q39280062-3EB270A1-4DAE-4C78-B60E-CE2833E9ADBA

Q39280062-4811A9B4-2A6C-48A3-86AC-45FCE6F7DC39

Q39280062-4EEF1CDE-7F4A-49BC-B9A4-D3BC9C4FE2D3

P2888

Q39280062-A1C00E06-CC6E-4A29-BF70-CC59B8ED2A52

P304

Q39280062-B5D73EF0-0721-481C-98C7-E81711917469

P31

Q39280062-788E07A3-8952-466D-BE34-DE8341A701A2

P356

Q39280062-1191A346-226A-46CA-A788-BC044EF69B6D

P433

Q39280062-6BDEE71A-679B-419C-AF95-0B3CFB1E0157

P478

Q39280062-DF5DDB26-3473-40A0-816F-6D8E78596AC5

P50

Q39280062-20903AB6-D3C7-4A49-9D89-6FFE8430CDEA

Q39280062-3BCD42FF-D4F2-4132-A27F-A67AA3646BEC

P577

Q39280062-27C56672-0D69-4553-80CA-26228FD76867

P5875

Q39280062-6395747B-4AED-4937-AE2B-90BC8BE823F5

P698

Q39280062-02985C8D-00A7-4C73-AE05-FA920FAF097D

P932

Q39280062-5A418807-783C-443D-8439-6D4164347579

P356

P1433

P1476

Inhibition of TGF-β signaling ...... ances tumor treatment efficacy

@en

P2093

L Zhang

http://www.w3.org/2001/XMLSchema#string

P Muranski

http://www.w3.org/2001/XMLSchema#string

R A Morgan

http://www.w3.org/2001/XMLSchema#string

S A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Z Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Tumor-specific Th17-polarized cells eradicate large established melanoma

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor

Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2.

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

P2888

P304

575-580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GT.2012.75

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2012-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230843103

http://www.w3.org/2001/XMLSchema#string

P698

22972494

http://www.w3.org/2001/XMLSchema#string

P932

6348484

http://www.w3.org/2001/XMLSchema#string